A federal advisory panel voted Thursday to ease rules on seven peptides, including BPC-157 and TB-500. The vote was close. It is not binding. The FDA has given no indication on whether it will adopt the suggestion. The move came after weeks of stakeholder sessions. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could alter how the agency handles a part of the wellness market that is growing very fast. Industry players are waiting to see if the agency takes up the plan. A representative for the regulator offered no deadline for a next step. Critics argue the change would grant more access to substances some say help. Safety voices warn that looser rules could invite misuse across a fast-scaling market. The vote only lays the groundwork for change, and the last word rests with the federal agency.